Ligand Pharmaceuticals Cash Flow Statement
NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ligand Pharmaceuticals free cash flow
In fiscal 2025, Ligand Pharmaceuticals generated $49.4 million of operating cash flow and spent $452,000 on capital expenditures. That left free cash flow of $48.9 million, a free-cash-flow margin of 18.2% of revenue. Free cash flow was down 48.6% from the prior year's $95.2 million.
Ligand Pharmaceuticals returned $15.0 million to shareholders through share repurchases, equal to 31% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Ligand Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 124.45M | -4.03M | 52.15M | -33.36M | 57.14M | -2.98M | 629.30M | 143.32M | 12.56M | -1.64M |
| Net Income growth (YoY) | — | -107.73% | — | -158.39% | — | -100.47% | +339.09% | +1041.45% | — | -100.72% |
| Depreciation & Amortization | 33.77M | 35.24M | 36.52M | 51.53M | 51.07M | 25.69M | 18.36M | 12.78M | 10.96M | 11.29M |
| Stock-Based Compensation | 46.85M | 41.09M | 25.74M | 60.28M | 38.78M | 30.73M | 24.52M | 20.85M | 24.91M | 18.89M |
| Change in Working Capital | -11.45M | 15.76M | -17.76M | 57.76M | -44.10M | -15.87M | 15.59M | -38.66M | -11.44M | -11.18M |
| Operating Cash Flow | 49.36M | 97.05M | 49.58M | 137.85M | 78.80M | 54.59M | -29.34M | 194.06M | 88.57M | 60.73M |
| Capital Expenditures | -452.00K | -1.82M | -3.52M | -17.92M | -8.76M | -4.46M | -2.55M | -887.00K | -2.16M | -1.85M |
| Investing Cash Flow | -377.32M | -143.66M | -11.68M | 163.62M | 30.52M | 231.65M | 466.92M | -423.27M | -79.18M | -134.41M |
| Share Repurchases | -15.00M | 0 | 0 | 0 | 0 | -78.00M | -453.05M | -122.87M | -1.97M | -3.90M |
| Debt Repaid | 0 | 0 | -76.85M | -260.95M | -155.76M | -222.21M | -27.32M | -217.67M | 0 | 0 |
| Financing Cash Flow | 428.22M | 97.14M | -59.95M | -275.99M | -137.76M | -310.55M | -485.17M | 328.58M | -7.52M | -4.99M |
| Net Change in Cash | 102.62M | 49.35M | -22.05M | 25.48M | -28.44M | -24.31M | -47.59M | 99.38M | 1.87M | -78.68M |
| Free Cash Flow | 48.91M | 95.23M | 46.06M | 119.93M | 70.04M | 50.13M | -31.89M | 193.17M | 86.41M | 58.88M |
This table shows 10 annual periods of Ligand Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow LGND's reporting calendar. What is a cash flow statement?